HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • HIV Drug Development Pipeline Update, Fall 2014 Edition

    HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. At IDWeek 2014 in Philadelphia, Paul Sax, M.D., made the case for this new generation of drugs, and provided an update on several of the most noteworthy candidates currently in development.

    17 November 2014 | The Body Pro
  • Scientists see mechanism for spontaneous HIV 'cure'

    French scientists claimed Tuesday to have found the genetic mechanism for a "spontaneous cure" in two HIV-infected men, proposing a new strategy for combating AIDS even as other experts urged caution.

    10 November 2014 | AFP / Yahoo News
  • Innovation in fixed-dose combos: HIV/AIDS therapeutics edition

    FDC drug development is evolving rapidly as the industry gains experience in manufacturing them and ushering them through the review process. The laws have changed towards a more favorable marketing climate. And finally, it is clear that FDCs are more than a way to improve adherence—though that will always be a prominent consideration. FDCs can shift the standard of care towards a more tolerable, patient-friendly, value-oriented approach to treatment, and in the final analysis, that approach to development bodes well for companies, payers, and most importantly, patients.

    07 November 2014 | BioPharma Dive
  • Viral Load Reductions Persist With Less Efavirenz for HIV

    The virologic responses with reduced-dose efavirenz at 48 weeks have proven durable out to 96 weeks, ENCORE1 study results show.

    07 November 2014 | Medscape (requires free registration)
  • Immune cells proposed as HIV hideout don't last in primate model

    The type of immune cell called macrophages, which have been proposed as a 'sanctuary site' of HIV in the brain and other organs, and as a possible cause of HIV-related brain impairment, don't live long enough to serve as reservoirs of HIV, a study in PLoS Pathogens finds.

    04 November 2014 | EATG
  • How Will Generic Drugs Affect HIV Treatment in the U.S.?

    In the U.S., in that many of the antiretroviral drugs that are commonly used today are approaching their patent expirations. So we can begin to conceptualize the use of generics in the U.S. and the potential cost savings. An Interview With Treatment Action Group's Tim Horn.

    31 October 2014 | The Body
  • Michel Sidibé: Thailand leads way to ending Aids

    This month, through its innovative Ending Aids by 2030 strategy, Thailand became the first country in Asia to offer HIV treatment to every person living with HIV.

    28 October 2014 | Bangkok Post
  • Effective treatments available for HIV patients not eligible for efavirenz regimens

    HIV drug regimens that do not include efavirenz are effective as first-line antiretroviral therapy, a new American clinical trial found. The finding is important for patients who are not eligible for treatment with efavirenz, including women considering becoming pregnant and patients with a history of severe psychiatric disorders.

    07 October 2014 | Science Daily
  • Why I Refused, Then Later Embraced, HIV Treatment

    "On good days, adhering to my pill is a positive affirmation of my life, an exercise in self-love. On bad days, it's just a pill I need to swallow, not terribly bitter but as mildly annoying as having to shave or tie my shoelaces every day. It's yet another thing to add to my list of things, but I do it anyway." Josh Kruger on his ambiguous relationship to HIV treatment.

    01 October 2014 | TheBody.com
  • PREZCOBIX™ now available for Canadians living with HIV

    Janssen Inc. announced today that PREZCOBIX™ (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. The new treatment option combining a protease inhibitor with a boosting agent reduces the number of pills required to manage HIV.

    18 September 2014 | Newswire.ca
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.